Successful treatment of Chronic Myelogenic Leukemia (CML) with imatinib after renal transplantation.
Chronic Myelogenic Leukemia (CML) is a rare malignant disorder after solid organ transplantation, especially in renal transplant recipients. Imatinib Mesylate is currently approved as first line treatment of CML. Most reports on CML are from kidney recipients who received azathioprine  in combination with cyclosporine and prednisolone as immunosuppressive therapy. We report a case with CML who was treated with Mycophenolate Mofetil.
Associate Professor of Hematology and Oncology, Uromia University of Medical Sciences, Iran. Makhdoomikhadijeh@yahoo.com.
Ali
A
Eishei Oskuei
Associate Professor of Nephrology, Nephrology and Kidney Transplant Research Center, Uromia, Iran.
Khadijeh
K
Makhdoomi
Assistant professor of Nephrology , Uromia University of Medical Sciences, Uromia, Iran.
Saeed
S
Abkhiz
Resident of Internal Medicine, Uromia University of Medical Sciences, Iran.
Sara
S
Vossoghian
Resident of Internal Medicine, Uromia University of Medical Sciences, Iran.
Mohsen
M
Farrokhpour
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D016572:Cyclosporine / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011239:Prednisolone / Q000009:adverse effects; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D016572:Cyclosporine; D000068877:Imatinib Mesylate; D011239:Prednisolone